Dr. Reddy's Laboratories Limited (DRREDDY)
Investor Presentation
AI summary
- Reported revenues ₹8,671 Cr, +1.5% YoY, +7% QoQ; EBITDA ₹1,783 Cr, margin 20.6%, +24% YoY
- PAT ₹925 Cr, +36% YoY; net cash surplus ₹2,502 Cr as of Sep 30, 2026
- North America revenues ₹2,489 Cr, +23% YoY; Emerging Markets ₹2,059 Cr, +24% YoY
- India revenues ₹1,851 Cr, +17% YoY; Europe ₹1,393 Cr, +1% YoY
- Partnered for India's 1st CDSCO approved dengue vaccine, launch H1 2027
- Expanded Gilead collaboration for HIV prevention drug in 120 countries
- CDMO business surpassed $100 million annual revenue
- Multiple regulatory inspections with observations responded within timelines
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 DRREDDY — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add DRREDDY to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Dr. Reddy's Laboratories Limited
Important.
The summary above is generated automatically from Dr. Reddy's Laboratories Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.